Information Provided By:
Fly News Breaks for January 13, 2016
RHHBY, SHPG
Jan 13, 2016 | 08:08 EDT
Bernstein believes that Roche's (RHHBY) new hemphilia drug, ACE910, poses some risk to Baxalta's hemopihlia treatments. However, the firm thinks that the risk taken by Shire with its acquisition of Baxalta is "more than fairly factored" into its stock price. The firm recommends buying Shire at current levels.
News For SHPG;RHHBY From the Last 2 Days
RHHBY
RHHBY
Apr 24, 2024 | 06:30 EDT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.